OTCMKTS:NWPHF Newron Pharmaceuticals (NWPHF) Stock Price, News & Analysis → Here’s how to start a “Weekend Side Hustle” from your sofa (From DTI) (Ad) Free NWPHF Stock Alerts $8.52 0.00 (0.00%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$8.52▼$8.5250-Day Range$8.52▼$8.5252-Week Range$5.22▼$8.55VolumeN/AAverage Volume1,525 shsMarket Capitalization$152.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Newron Pharmaceuticals alerts: Email Address Ad Wealthpin ProOne trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. About Newron Pharmaceuticals Stock (OTCMKTS:NWPHF)Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.Read More NWPHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NWPHF Stock News HeadlinesApril 8, 2024 | finance.yahoo.comData from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)March 19, 2024 | finance.yahoo.comNewron Presents 2023 Financial Results and Provides 2024 OutlookApril 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”March 15, 2024 | finance.yahoo.comNewron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreementMarch 13, 2024 | finance.yahoo.comBreakeven Is Near for Newron Pharmaceuticals S.p.A. (VTX:NWRN)January 4, 2024 | finance.yahoo.comNewron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)January 2, 2024 | msn.comNewron enrols all subjects in schizophrenia treatment trialDecember 29, 2023 | markets.businessinsider.comEQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with EvenamideApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… December 13, 2023 | morningstar.comNewron Pharmaceuticals SpA NWRNOctober 9, 2023 | finance.yahoo.comNewron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry CriteriaOctober 4, 2023 | businesswire.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36 th European College of Neuropsychopharmacology CongressOctober 4, 2023 | finance.yahoo.comNewron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology CongressOctober 2, 2023 | markets.businessinsider.comEQS-News: Newron appoints Margarita Chavez as board advisorOctober 2, 2023 | finance.yahoo.comNewron Appoints Margarita Chavez as Board AdvisorAugust 4, 2023 | finance.yahoo.comNewron Announces H1 2023 Results and Provides R&D UpdateAugust 4, 2023 | markets.businessinsider.comEQS-News: Newron announces H1 2023 results and provides R&D updateJune 15, 2023 | finance.yahoo.comInvesting in Newron Pharmaceuticals (VTX:NWRN) a year ago would have delivered you a 187% gainMay 2, 2023 | markets.businessinsider.comEQS-News: Newron announces Senior Management Team changesMay 2, 2023 | uk.finance.yahoo.comNewron announces Senior Management Team changesApril 27, 2023 | finance.yahoo.comAnalysts Expect Newron Pharmaceuticals S.p.A. (VTX:NWRN) To Breakeven SoonApril 18, 2023 | uk.finance.yahoo.comNewron announces AGM 2023 resultsApril 18, 2023 | markets.businessinsider.comEQS-News: Newron announces AGM 2023 resultsMarch 28, 2023 | markets.businessinsider.comEQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 28, 2023 | uk.finance.yahoo.comNewron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of PsychiatryMarch 17, 2023 | markets.businessinsider.comEQS-News: Newron to present at the 31st European Congress of PsychiatryMarch 14, 2023 | uk.finance.yahoo.comNewron announces 2022 financial results and provides outlook for 2023See More Headlines Receive NWPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Newron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NWPHF CUSIPN/A CIKN/A Webwww.newron.com Phone(902) 610-3461Fax39-02-6103-4654Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.82 million Price / Sales22.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book40.57Miscellaneous Outstanding Shares17,850,000Free FloatN/AMarket Cap$152.08 million OptionableNot Optionable Beta0.53 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Stefan Weber (Age 59)CEO & Executive Director Comp: $506.78kMr. Roberto GalliChief Financial OfficerMr. Filippo MoriggiaVice President of OperationsDr. Ravi Anand M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $1.17MMs. Laura FaravelliVice President of Business DevelopmentKey CompetitorsProMIS NeurosciencesNASDAQ:PMNCara TherapeuticsNASDAQ:CARABriaCell TherapeuticsNASDAQ:BCTXUnicycive TherapeuticsNASDAQ:UNCYMarker TherapeuticsNASDAQ:MRKRView All Competitors NWPHF Stock Analysis - Frequently Asked Questions How have NWPHF shares performed in 2024? Newron Pharmaceuticals' stock was trading at $5.22 at the beginning of the year. Since then, NWPHF stock has increased by 63.2% and is now trading at $8.52. View the best growth stocks for 2024 here. Are investors shorting Newron Pharmaceuticals? Newron Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 44,600 shares, an increase of 50.7% from the March 15th total of 29,600 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days. View Newron Pharmaceuticals' Short Interest. How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NWPHF) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Newron Pharmaceuticals S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
